Details of the Drug Combination

General Information of Drug Combination (ID: DC6FL5U)

Drug Combination Name
Levofloxacin Amoxicillin
Indication
Disease Entry Status REF
Functional Dyspepsia Phase 4 [1]
Component Drugs Levofloxacin   DMS60RB Amoxicillin   DMUYNEI
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Levofloxacin
Disease Entry ICD 11 Status REF
Acute maxillary sinusitis N.A. Approved [2]
Anthrax 1B97 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Latent tuberculosis infection N.A. Approved [2]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Pyelonephritis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Streptococcal pneumonia N.A. Approved [2]
Pneumonia caused by chlamydia N.A. Investigative [2]
Levofloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [6]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [6]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEP0IWS A0A378EHS6_KLEPR Metabolism [9]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dihydrofolate reductase (DHFR) OT3DVIGM DYR_HUMAN Decreases Activity [10]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [11]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Decreases Expression [11]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [11]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Decreases Expression [11]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [11]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) OT1SLUZH TSG6_HUMAN Decreases Expression [11]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Increases Expression [11]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Decreases Expression [11]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [12]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)
Indication(s) of Amoxicillin
Disease Entry ICD 11 Status REF
Acute otitis media AB00 Approved [4]
Bacterial infection 1A00-1C4Z Approved [5]
Staphylococcus aureus infection N.A. Approved [4]
Streptococcal pneumonia N.A. Approved [4]
Urinary tract infection GC08 Approved [4]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [4]
Sinusitis CA0A.Z Investigative [4]
Amoxicillin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Cell membrane (Bact CM) TTXT4D5 NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Amoxicillin Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [14]
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [14]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [15]
------------------------------------------------------------------------------------
Amoxicillin Interacts with 46 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [16]
Beta-lactamase (blaB) DED0TBR A0A414M273_9BACE Metabolism [17]
Beta-lactamase (blaB) DEX8KJO A6NX15_9FIRM Metabolism [18]
Beta-lactamase (blaB) DEAYSTX C0W968_9FIRM Metabolism [19]
Beta-lactamase (blaB) DERGEVU C3WC84_FUSMR Metabolism [20]
Beta-lactamase (blaB) DEV0KWQ Q8KT52_9BACT Metabolism [21]
Beta-lactamase (blaB) DEQMISO F9Z530_ODOSD Metabolism [20]
Beta-lactamase (blaB) DEHFJ4G Q8KT51_9BACT Metabolism [20]
Beta-lactamase (blaB) DEHPJRC Q8KT60_9BACT Metabolism [20]
Beta-lactamase (blaB) DEITMS0 Q9XBM2_ACIFE Metabolism [22]
N-acylhomoserine lactone acylase (lacA) DEIU0XN A0A0A1VBK6_9BURK Metabolism [23]
Beta-lactamase (blaB) DET9I1W BLAC_BACUN Metabolism [24]
Beta-lactamase (blaB) DE7IH52 AMPC_CITFR Metabolism [21]
Beta-lactamase (blaB) DENJ2SQ BLAB_BACFG Metabolism [24]
Beta-lactamase (blaB) DE5HV8P A0A4Q5I6I2_9BACE Metabolism [24]
Beta-lactamase (blaB) DE47ARF B5WXV2_9BACT Metabolism [25]
Beta-lactamase (blaB) DEG2PK9 B5WXV3_BACOV Metabolism [24]
Beta-lactamase (blaB) DEWHJ7A B5WXV7_BACT4 Metabolism [24]
Beta-lactamase (blaB) DEU1RXB BLAC_BACVU Metabolism [24]
Beta-lactamase (blaB) DETDS7E A0A2S0LB67_9FLAO Metabolism [21]
Beta-lactamase (blaB) DE37FJH C6JIU1_FUSVA Metabolism [20]
Beta-lactamase (blaB) DEC7JEF A0A1S1G219_9NEIS Metabolism [21]
Beta-lactamase (blaB) DEP7MN1 Q9X4S7_PREIN Metabolism [26]
Beta-lactamase (blaB) DEAILCM A0A246EJV2_9BACT Metabolism [26]
Beta-lactamase (blaB) DET4XFN Q8KT59_9BACT Metabolism [21]
Metallo-beta-lactamase (blaM) DEPCQ12 Q68K11_ALCXX Metabolism [27]
Beta-lactamase (blaB) DEACNTL Q2F4C6_SHISO Metabolism [28]
Beta-lactamase (blaB) DEE8742 O32372_CAPOC Metabolism [29]
Beta-lactamase (blaB) DEY09SU C9MN73_9BACT Metabolism [21]
Beta-lactamase (blaB) DEQLVCA C9LD75_9BACT Metabolism [26]
Beta-lactamase (blaB) DE2IL34 C2M7J0_CAPGI Metabolism [29]
Beta-lactamase (blaB) DE1NJIW B6VMJ3_PHOAA Metabolism [30]
Beta-lactamase (blaB) DEDIMN9 A0A413GBG0_9BACE Metabolism [24]
Beta-lactamase (blaB) DEJ8X2W A0A412YFL9_9BACE Metabolism [24]
Beta-lactamase (blaB) DEFEVNH A0A381DV31_9FLAO Metabolism [29]
Beta-lactamase (blaB) DEAPGXV A0A347B2J2_9BACT Metabolism [21]
Beta-lactamase (blaB) DE0PDVC A0A2A3N1K0_CAPSP Metabolism [29]
Beta-lactamase (blaB) DEQL32N A0A250F962_9FLAO Metabolism [29]
Beta-lactamase (blaB) DE9HF0I A0A120A1C6_BACSE Metabolism [24]
Beta-lactamase (blaB) DESHI6O A0A108T9G3_9BACE Metabolism [24]
Beta-lactamase (blaB) DEZS3N4 A0A069QS91_PRELO Metabolism [21]
Beta-lactamase (blaB) DE5NSUX A0A095XPV0_9FIRM Metabolism [21]
New delhi metallo-beta-lactamase NDM-1 (blaNDM) DEBGCYQ A0A345N7K5_SALET Metabolism [31]
Beta-lactamase (blaB) DEW193R BLA1_KLEPN Metabolism [27]
Metallo-beta-lactamase (blaM) DEK9VG2 BLAN1_KLEPN Metabolism [27]
Beta-lactamase (blaB) DEQ1CTE A0A2T4TNV5_9BACT Metabolism [32]
------------------------------------------------------------------------------------
⏷ Show the Full List of 46 DME(s)
Amoxicillin Interacts with 15 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Affects Expression [33]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [33]
C-C chemokine receptor type 9 (CCR9) OT5FSOD8 CCR9_HUMAN Increases ADR [34]
C-C chemokine receptor type 4 (CCR4) OT68KZ9B CCR4_HUMAN Increases ADR [34]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Increases ADR [35]
C-X-C chemokine receptor type 3 (CXCR3) OTIGS220 CXCR3_HUMAN Increases ADR [34]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Increases Expression [36]
Cytochrome P450 11B2, mitochondrial (CYP11B2) OTIOLWYN C11B2_HUMAN Increases Expression [36]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Activity [37]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Increases Expression [38]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [38]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [38]
C-X-C motif chemokine 10 (CXCL10) OTTLQ6S0 CXL10_HUMAN Decreases Expression [39]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [39]
Organic solute transporter subunit alpha (SLC51A) OTDJRZ0P OSTA_HUMAN Increases Expression [40]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Antimicrobial Susceptibility Testing DC5JOLC N. A. Phase 4 [41]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01667718) Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
2 Levofloxacin FDA Label
3 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
4 Amoxicillin FDA Label
5 Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
9 Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
10 Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity. J Biochem Mol Toxicol. 2015 Mar;29(3):135-9.
11 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
12 TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
13 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
14 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
15 The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
16 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
17 Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res. 2013 Mar;57(3):523-35.
18 The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin. Br J Oral Maxillofac Surg. 1990 Jun;28(3):180-4.
19 ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300.
20 Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
21 Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
22 ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9.
23 A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
24 Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
25 Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
26 Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
27 Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
28 IncU plasmid harbouring bla CTX-M-8 in multidrug-resistant Shigella sonnei in Brazil. J Glob Antimicrob Resist. 2018 Sep;14:99-100.
29 High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
30 Yersinia enterocolitica and Photorhabdus asymbiotica beta-lactamases BlaA are exported by the twin-arginine translocation pathway. Int J Med Microbiol. 2013 Jan;303(1):16-24.
31 Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
32 High prevalence of cfxA beta-lactamase in aminopenicillin-resistant Prevotella strains isolated from periodontal pockets. Oral Microbiol Immunol. 2002 Apr;17(2):85-8.
33 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
34 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
35 HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013.
36 Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):142-53.
37 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
38 Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
39 Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
40 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
41 ClinicalTrials.gov (NCT03139253) Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment